McClure Matthew W. 4
4 · Aligos Therapeutics, Inc. · Filed Feb 28, 2024
Insider Transaction Report
Form 4
McClure Matthew W.
Chief Medical Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2024-02-27−255,626→ 0 totalExercise: $16.18From: 2021-01-01Exp: 2030-12-01→ Common Stock (255,626 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-02-27−92,000→ 0 totalExercise: $3.06From: 2022-03-04Exp: 2032-02-04→ Common Stock (92,000 underlying) - Award
Stock Option (Right to Buy)
2024-02-28+75,183→ 75,183 totalExercise: $0.96Exp: 2030-12-01→ Common Stock (75,183 underlying) - Award
Stock Option (Right to Buy)
2024-02-28+16,428→ 16,428 totalExercise: $0.96Exp: 2032-02-04→ Common Stock (16,428 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-02-27−23,000→ 0 totalExercise: $3.06From: 2025-02-04Exp: 2032-02-04→ Common Stock (23,000 underlying) - Award
Stock Option (Right to Buy)
2024-02-28+65,713→ 65,713 totalExercise: $0.96Exp: 2032-02-04→ Common Stock (65,713 underlying)
Footnotes (5)
- [F1]On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 255,626 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 75,183 shares, having an exercise price of $0.96 per share.
- [F2]On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 92,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 65,713 shares, having an exercise price of $0.96 per share.
- [F3]On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 23,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 16,428 shares, having an exercise price of $0.96 per share.
- [F4]The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary.
- [F5]The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date.